foxo4-dri senolytic peptide human trial 2024 Senolytics: from pharmacological inhibitors to immunotherapies, a promising future for patients' treatment Peptide inhibitors targeting FOXO4-p53 interactions

Name: foxo4-dri senolytic peptide human trial 2024 Senolytics: from pharmacological inhibitors to immunotherapies, a promising future for patients' treatment Peptide inhibitors targeting FOXO4-p53 interactions
Brand: www.allread.ai
SKU: 37107795959
Price: 23.64 USD
Availability: InStock
Rating: 4.814500000000001 (28 reviews)

SKU: 37107795959

4.8

DKK23.64 DKK48.64

Pay in 4 interest-free payments of $5.91 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 1 - Aug 6

Live Spec

Peptide inhibitors targeting FOXO4 p53 interactions and inducing senescent cancer cell specific apoptosis bioRxiv Peptide Inhibitors Targeting FOXO4 p53 Interactions and Inducing Senescent Cancer Cell specific Apoptosis Journal of Medicinal Chemistry FOXO4 DRI alleviates age related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice Aging foxo4 dri senolytic peptide human trial Computational design of targeting FOXO4. a, Domains of FOXO4 foxo4 dri senolytic 2024 study FOXO4 DRI 10mg D Retro Inverso PPI Peptide VPeptide FOXO4 DRI Canada: Ultra Pure Peptide for Senolytic, Cellular Aging & Longevity Pathway Research Senolytic Peptide FOXO4 DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes PMC

Store: www.allread.ai · Domain: www.allread.ai

Description

BPC-157 (Body Protecting Compound-157) is a synthetic pentadecapeptide derived from a protective protein in human gastric juice